ConductScience.org, home
ULBP1: UL16 binding protein 1
API referenceFor AI assistants

Gene · 80329

Papers1,302

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

1 to 20 of 1,302

Download this page as JSON
TitleJournalYearPMIDFound bySource
ULBP1 is a prognostic biomarker associated with immune suppression in breast cancer.Front Oncol202642718478PubTator, text miningPubMed
KRASG12D inhibition reprograms the tumor-induced immunosuppressive environment and enhances NK cell-mediated antitumor immunity.Sci Adv202642490421PubTator, text miningPubMed
Cerebrospinal Fluid Transcriptional Immune Pathways Linked to Survival in HIV-Associated Tuberculous Meningitis.J Infect Dis202642313402PubTator, text miningPubMed
Increased ULBP1 by doxorubicin sensitizes neuroblastoma to γδT-cell cytotoxicity.J Immunol202642309532PubTator, text miningPubMed
Multi-mechanistic mitochondria-mediated N-methylated YKWYYRGAA-decorated nano-chitosan conjugate carrier for treatment of NRAS-mutant-harbouring lung carcinoma.Carbohydr Polym202642230031PubTator, text miningPubMed
Xylooligosaccharides ameliorate intestinal barrier injury by inhibiting apoptosis, RhoA/ROCK/MLCK signaling and NKG2DLs in intestinal epithelial cells.Food Res Int202642116516PubTator, text miningPubMed
Unraveling the implications of ULBP1 expression from pan-cancer to head and neck squamous cell carcinoma.Sci Rep202642106428PubTator, text miningPubMed
Metformin drives HIF-1α-mediated dual metabolic reprogramming to enhance γδ T cell therapy in triple-negative breast cancer.Cancer Immunol Immunother202641925872PubTator, text miningPubMed
Emerging immune checkpoint targets and combination strategies in blood cancer immunotherapy.Ann Hematol202641915070PubTator, text miningPubMed
cGAS/STING-mediated upregulation of NKG2D ligands in LSCs contributes to enhanced sensitivity to NK cells.Front Oncol202641809821PubTator, text miningPubMed
The Role of DNA Methylation in Osteosarcoma Pathogenesis and Therapy.Onco Targets Ther202641768085PubTator, text miningPubMed
NKG2D CAR-T cells for solid tumor immunotherapy: advances, challenges, and future directions.Front Immunol202641756289PubTator, text miningPubMed
NKGD2 Ligands (NKG2DLs) in Breast Cancer: In Silico Analysis and Narrative Review.Int J Mol Sci202641751981PubTator, text miningPubMed
Erastin-induced ferroptosis enhances natural killer cell anti-tumor activity and offers therapeutic potential in neuroblastoma.Front Immunol202641743726PubTator, text miningPubMed
Comprehensive analysis of mitochondrial unfolded protein response related genes for prognosis and therapeutic response in pancreatic cancer.Front Immunol202641727504PubTator, text miningPubMed
The impact of p53 mutation on tumor immune evasion: mechanistic insights and clinical implications.Front Immunol202641727427PubTator, text miningPubMed
Rewiring melanoma cell fate: TRPM8 modulators trigger apoptosis and boost NK cell cytotoxicity.Cell Death Dis202641688418PubTator, text miningPubMed
Stem cell engineering for the generation of allogeneic CAR-directed natural killer T cells targeting endometrial carcinoma.Exp Hematol Oncol202641612507PubTator, text miningPubMed
Cyclosporin A indirectly suppresses NK cells activity in renal microvascular inflammation by inducing ubiquitination-dependent degradation of ULBP1.Int Immunopharmacol202641297348PubTator, text miningPubMed
The ATR inhibitor tuvusertib (M1774) sensitizes prostate carcinoma to natural killer cell-mediated cytotoxicity, which is further augmented by the IL-15 receptor superagonist N-803.Cancer Immunol Immunother202541417226PubTator, text miningPubMed

gene-search-2026-11-11-0.2.0

Next page

Sources 12

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
  • GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
  • HGNCCC0
  • NCBI GenePublic domain (US government)
  • NIH's project files and grant-paper linksPublic domain
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
  • GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
  • HGNCCC0: https://www.genenames.org/about/license/
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/genes/v1/80329/papers

API referenceFor AI assistants